Anna-Kaisa Lehtivarjo

VP Quality Assurance Resolution Therapeutics

Conference Day One - Wednesday 10 March 2027

10:00 AM PANEL DISCUSSION: THE DECISION MATRIX: SPEED vs COST vs QUALITY

Selecting the right CDMO partner is one of the most critical decisions in pharmaceutical development. The right partnership can accelerate timelines, control costs, ensure regulatory compliance, and deliver the quality required to bring safe and effective medicines to patients. Yet, when trade-offs arise, does speed, cost or quality take priority?

In an increasingly competitive market, pharmaceutical companies are constantly balancing the golden triangle of speed, cost, and quality. Common questions asked include: Is it worth paying a premium to reach the market faster? When can cost efficiencies be achieved without compromising quality?

Join senior leaders from three pharmaceutical companies as they share how to weigh these priorities and select CDMO partners. Through practical examples, the panel will explore the decision-making frameworks they use, the compromises they are willing to make, and the qualities they value most in a long-term manufacturing partner.

Key discussion points include:

Understand how pharmaceutical companies prioritise speed, cost, and quality when evaluating and selecting CDMO partners.
Discover when speed to market justifies additional investment and when cost becomes the deciding factor.
Learn practical strategies for balancing speed, cost, and quality across manufacturing.
Explore the criteria that matter beyond the traditional golden triangle, including technical expertise, regulatory track record, communication, flexibility, innovation, and cultural fit.

Check out the incredible speaker line-up to see who will be joining Anna-Kaisa.

Download The Latest Agenda

In Partnership With:

QUESTIONS?

Address: IQPC Ltd, 129 Wilton Road,
London SW1V 1JZ
Telephone: +44 (0) 113 210 042
Fax: 44 (0) 207 368 9301
Email: enquire@iqpc.co.uk